Approaches and Metrics in Fraily Patients During COVID-19 Era — COMETA  

Frailty Clinical Trial

Official title: Development of Approaches and Metrics to Measure the Impact and Improve the Clinical Outcomes of Patients With Frailty in the Era of COVID-19.

Status Completed

Clinical Trial Summary

The COVID-19 pandemic started in December 2019 in Wuhan, the Chinese province of Hubei. Compared to the period of the first epidemic wave (March to May 2020), in the period of the second epidemic wave (October 2020 to July 2021), deceased people have a more significant clinical complexit, as demonstrated by the higher number of comorbidities.The need to allocate significant amounts of healthcare resources to the COVID-19 emergency, deferral of routine healthcare visits, and invitation to avoid medical controls, if not strictly necessary, may have led to interruptions of disease management undersupply of chronic treatments. Consequently, the health status of patients with chronic pathologic conditions have worsened during and beyond the crisis. Patients with cancer, autoimmune disease, and immune deficiencies represented populations with varying immunocompetence, which made translate into higher susceptibility to SARS-CoV-2 and, for this reason, we defined them as frail populations.The main goal of the study was to propel the field of COVID-19 impact on particularly vulnerable categories of patients. The findings of this study could aid in determining the conditions under which healthcare organizations must operate in the event of a pandemic in order to protect patient's rights to care.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Frailty
• Immune Deficiency
• Immunologic Deficiency Syndromes
• Oncology

• NCT number: NCT05792891
• Study type: Observational
• Source: Regina Elena Cancer Institute
• Status: Completed
• Start date: December 22, 2020
• Completion date: November 23, 2022